UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S129-S130

Portell, Craig A.

2024

Volltextzugriff (PDF)

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib

JAAD Case Reports, 2024-05, Vol.47, p.47-49

2024

Volltextzugriff (PDF)

Risk factors for the development of atrial fibrillation on ibrutinib treatment

Leukemia & lymphoma, 2019-05, Vol.60 (6), p.1447-1453

2019

Volltextzugriff (PDF)

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib

Leukemia & lymphoma, 2019-03, Vol.60 (4), p.1000-1005

2019

Volltextzugriff (PDF)

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems

Mediterranean journal of hematology and infectious diseases, 2024, Vol.16 (1), p.e2024061

2024

Volltextzugriff (PDF)

Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia

IDCases, 2021-01, Vol.26, p.e01263, Article e01263

2021

Volltextzugriff (PDF)

Zanubrutinib-induced petechial ecchymotic reaction in a previously irradiated area in a patient with chronic lymphocytic leukemia

JAAD Case Reports, 2024-04, Vol.46, p.70-72

2024

Volltextzugriff (PDF)

An update on the efficacy of Venetoclax for chronic lymphocytic leukemia

Expert opinion on pharmacotherapy, 2023-07, Vol.24 (11), p.1307-1316

2023

Volltextzugriff (PDF)

An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia

Expert review of hematology, 2020-10, Vol.13 (10), p.1039-1046

2020

Volltextzugriff (PDF)

Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy

Process biochemistry (1991), 2024-08, Vol.143, p.44-59

2024

Volltextzugriff (PDF)

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Allergy (Copenhagen), 2022-08, Vol.77 (8), p.2355-2366

2022

Volltextzugriff (PDF)

Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy

International immunopharmacology, 2024-06, Vol.135, p.112265-112265, Article 112265

Rao, Asad Gul

2024

Volltextzugriff (PDF)

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Leukemia & lymphoma, 2021-09, Vol.62 (11), p.2612-2624

2021

Volltextzugriff (PDF)

Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

Journal of rheumatology, 2021-07, Vol.48 (7), p.969-976

2021

Volltextzugriff (PDF)

CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S520-S521

2023

Volltextzugriff (PDF)

CLL-194 Ibrutinib for Treatment of Relapsed-Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison of 3 Randomized Phase III Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S322-S323

2023

Volltextzugriff (PDF)

CLL-428 Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S327-S328

2023

Volltextzugriff (PDF)

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

Journal of allergy and clinical immunology, 2022-12, Vol.150 (6), p.1498-1506.e2

2022

Volltextzugriff (PDF)

CLL-415 Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S353-S353

2024

Volltextzugriff (PDF)

ABCL-579 Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S483-S484

2024

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study

International immunopharmacology, 2024-01, Vol.126, p.111285-111285, Article 111285

2024

Volltextzugriff (PDF)

BTK Inhibitor Therapy Can be Stopped in CLL

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S104-S105

2024

Volltextzugriff (PDF)

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease

International journal of molecular sciences, 2021-04, Vol.22 (8), p.3840

2021

Volltextzugriff (PDF)

Virtual screening and structure-activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis

Journal of biomolecular structure & dynamics, 2023-12, Vol.41 (24), p.15219-15233

2023

Volltextzugriff (PDF)

1 – 25 von 863

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(830)
Mit Volltextzugriff
(742)

Publikationsform

Artikel
(858)
Buchkapitel
(5)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(762)
Life Sciences & Biomedicine
(720)
Bruton's Tyrosine Kinase
(514)
Humans
(477)
Protein-Tyrosine Kinase
(323)
Kinases
(307)
Oncology
(248)
Tyrosine
(242)
Chronic Lymphocytic Leukemia
(228)
Ibrutinib
(222)
Lymphoma
(220)
Leukemia
(212)
Enzyme Inhibitors
(203)
Hematology
(203)
Lymphocytes B
(185)
Patients
(166)
Animals
(165)
Pharmacology & Pharmacy
(156)
Protein Kinase Inhibitors - Pharmacology
(152)
Clinical Trials
(148)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(22)

Menü

Weitere Dienste

Einstellungen

Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib

Risk factors for the development of atrial fibrillation on ibrutinib treatment

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems

Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia

Zanubrutinib-induced petechial ecchymotic reaction in a previously irradiated area in a patient with chronic lymphocytic leukemia

An update on the efficacy of Venetoclax for chronic lymphocytic leukemia

An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

CLL-194 Ibrutinib for Treatment of Relapsed-Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison of 3 Randomized Phase III Trials

CLL-428 Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

CLL-415 Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

ABCL-579 Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study

Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study

BTK Inhibitor Therapy Can be Stopped in CLL

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease

Virtual screening and structure-activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis

Suchergebnisse filtern